Senstem Pharmaceuticals' new anti-insomnia drug approved.

According to the official website of the National Medical Products Administration, the anti-insomnia drug Levadex hydrochloride tablets, developed in collaboration by CSPC Pharmaceutical Group and Swiss company Idorsia, have been approved. This drug is a dual orexin receptor antagonist and belongs to the next generation of anti-insomnia medications. In November 2022, CSPC Pharmaceutical Group and Idorsia signed an exclusive license agreement, granting CSPC Pharmaceutical Group the exclusive rights to develop and commercialize Levadex in China.